Following IL-2 therapy, clinical treatment of ccRCC moved more towards the use of tyrosine kinase inhibitors (TKIs) targeting VEGFA/VEGFR pathway and neoangiogenesis, including sunitinib, sorafenib, and cabozantinib for treating ccRCC patients [74,75,76]. Here, KDR is linked to nonpapillary renal cell carcinoma.